- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02421016
Test Efficacy With Bioresorbable Polymer Coating Versus Bioresorbable Polymer Backbone (ISAR-RESORB)
A Prospective, Randomized Trial of SYNERGY Bioresorbable Polymer Coated Stents Versus ABSORB Bioresorbable Backbone Stents in Patients Undergoing Coronary Stenting (ISAR-RESORB)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation currently represents the dominant treatment strategy in patients undergoing catheter intervention. However, effective neointimal suppression occurs at the cost of a systematic delay in arterial healing in comparison with after bare metal stenting. This underlies a small but significant increased risk of stent thrombosis after DES implantation in comparison with bare metal stent implantation as well as a possible excess of in-stent neoatheroma formation. To address this issue recent technological advances have focused on bioresorbable polymer coatings and the development of stents with fully resorbable backbones.
Newer generation metallic DES with bioresorbable polymer coatings have been shown to improve vascular healing after coronary stenting. In particular a novel thin-strut bioresorbable polymer everolimus-eluting stent (EES, SYNERGY, Boston Scientific Corp., Natick, MA, USA) has shown high angiographic antirestenotic efficacy as well as high clinical efficacy and safety in early randomized trials. In addition, DES with bioresorbable backbones represent an alternative approach to ensure short-term vessel scaffolding and drug delivery with enhanced vessel healing. The everolimus-eluting bioresorbable backbone stent (ABSORB bioresorbable vascular scaffold [BVS], Abbott Vascular, Santa Rosa, CA, USA) is the most-extensively studied device in this class and early reports in selected patients show encouraging clinical results. However requirement for thicker stent struts and more careful lesion preparation has led to concerns that potential clinical benefits may be offset by erosion of early antirestenotic efficacy and occurrence of clinical events related to limitations of device deployment.
At present there is a lack of randomized clinical trial data examining outcomes of patients treated with these two alternative strategies. The aim of the current ISAR-RESORB study is to test the clinical performance of the bioresorbable-polymer SYNERGY with that of the ABSORB BVS in patients undergoing PCI of de novo coronary lesions. The primary endpoint will be percentage diameter stenosis at protocol-mandated 6-8 month angiographic follow-up. Secondary clinical endpoint will be assessed at 12 months. Sample size calculation is based on a superiority hypothesis for SYNERGY versus ABSORB BVS. It is planned to enrol a total of 230 patients.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Robert Byrne, MB BCh PhD
- Phone Number: 4587 +49 89 1218
- Email: byrne@dhm.mhn.de
Study Contact Backup
- Name: Salvatore Cassese, MD
- Phone Number: 4578 +49 89 1218
- Email: Cassese@dhm.mhn.de
Study Locations
-
-
Bavaria
-
Munich, Bavaria, Germany, 80636
- Recruiting
- Deutsches Herzzentrum München
-
Contact:
- Robert Byrne, MB BCh PhD
- Phone Number: 4587 +49-89-1218-
- Email: byrne@dhm.mhn.de
-
Contact:
- Salvatore Cassese, MD
- Phone Number: 4578 +49-89-1218-
- Email: cassese@dhm.mhn.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients 18 years or older with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in native coronary vessels (max. 2 lesions in 2 separate vessels)
- Reference diameter ≥2.5 mm and ≤3.9 mm
- Lesion length <28 mm
- Written, informed consent by the patient for participation in the study
Exclusion Criteria:
- Cardiogenic shock
- Acute ST-elevation myocardial infarction within 48 hours from symptom onset.
- Target lesion located in left main trunk or bypass graft
- Severe calcification of the lesion
- Target lesion contains a side branch (diameter ≥2mm) or a bifurcation or is located 2 mm away from a bifurcation
- Ostial lesions
- Severe vessel tortuosity
- Renal insufficiency (most recent serum creatinine within the last 72h prior to randomization > 2 mg/dl or 177 µmol/l)
- Malignancies or other co-morbid conditions with life expectancy less than 12 months or that may result in protocol non-compliance
- Pregnancy, present (positive pregnancy test), suspected or planned, breast feeding
- Contraindications or allergy to platinum, chromium, everolimus or the inability to take antiplatelet therapy for at least 6 months after stenting; known allergy to PLLA, PDLLA or PLGA polymer
- Previous enrollment in this trial
- Patient's inability to fully cooperate with the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SYNERGY EES
Bioresorbable polymer everolimus-eluting stent
|
Bioresorbable polymer everolimus-eluting stent
|
Active Comparator: ABSORB [BVS]
Everolimus-eluting bioresorbable backbone stent
|
Everolimus-eluting bioresorbable backbone stent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage diameter stenosis (in-stent) by quantitative coronary angiography analysis
Time Frame: at 6-8 months
|
at 6-8 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Composite of cardiac death/target vessel-myocardial infarction (MI)/ target lesion revascularization (TLR) (Device-oriented composite endpoint)
Time Frame: at 12 months
|
at 12 months
|
Composite of death/any MI/all revascularization (Patient-oriented composite endpoint)
Time Frame: at 12 months
|
at 12 months
|
Composite of cardiovascular death or MI
Time Frame: at 12 months
|
at 12 months
|
Stent Thrombosis
Time Frame: at 12 months
|
at 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Robert Byrne, MB BCh PhD, Deutsches Herzzentrum München
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GE IDE No S03914
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Stenosis
-
Biotronik (Beijing) Medical Device Ltd.Biotronik AGEnrolling by invitationNative Coronary Artery Stenosis | In-Stent Stenosis (Restenosis) of Coronary Artery StentChina
-
Axetis AGUnknownNative Coronary Artery StenosisNetherlands
-
Fundación Pública Andaluza Progreso y SaludUnknownUnprotected Left Main Coronary Artery StenosisSpain
-
ECRI bvBoston Scientific Corporation; Philips HealthcareActive, not recruitingLeft Main Coronary Artery StenosisSpain, United Kingdom, Italy
-
Institut Mutualiste MontsourisCompletedLeft Main Coronary Artery StenosisFrance
-
Tryton Medical, Inc.UnknownLeft Main Coronary Artery StenosisGermany
-
Columbia UniversityRecruitingLeft Anterior Descending Coronary Artery StenosisUnited States
-
Das Radiologische ZentrumHeidelberg UniversityRecruiting
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
-
Heinrich-Heine University, DuesseldorfCompletedCoronary Artery Stenosis of Unclear Hemodynamic RelevanceGermany
Clinical Trials on SYNERGY EES
-
A.O. Ospedale Papa Giovanni XXIIIUnknown
-
AtriCure, Inc.CompletedPersistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationUnited States
-
Nandan Lad, M.D., Ph.D.RecruitingSpinal Cord Injury at T1-T12 Level | Traumatic Thoracic Spinal Cord Contusion | Thoracic Spinal Cord Trauma | Traumatic Thoracic Spinal Cord Laceration | Post-Traumatic Thoracic Myelopathy | Traumatic Thoracic Spinal Cord MyelopathyUnited States
-
ECRI bvBoston Scientific Corporation; Volcano CorporationCompletedHeart Diseases | Cardiovascular Diseases | 3 Vessel Coronary Artery DiseaseNetherlands, Poland, Spain, United Kingdom
-
Buddhist Tzu Chi General HospitalRecruiting
-
Jung-min AhnCardioVascular Research Foundation, KoreaRecruitingMyocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Artery Disease | Coronary DiseaseKorea, Republic of
-
Synergy Spine SolutionsPacific Clinical Research GroupRecruiting
-
Medtronic Cardiac Rhythm and Heart FailureCompletedHeart FailureBelgium, Germany, United Kingdom, Italy, Slovakia
-
Center For SightScience in VisionCompleted
-
Center For SightScience in VisionCompleted